The assay identifies methylation patterns in the circulating tumour DNA in blood. Credit: fernando zhiminaicela from Pixabay.

The US Food and Drug Administration (FDA) has granted breakthrough device designation to Singlera Genomics’ PDACatch liquid biopsy assay.

The new DNA methylation-based assay is intended to identify pancreatic adenocarcinoma in individuals at high disease risk.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

PDACatch is based on the company’s MethylTitan platform, which deploys a library construction approach and methylation haplotypes to yield better conversion rates and cancer detection sensitivity.

Previously, the technology was shown to enable the early identification of five cancer types four years before conventional diagnosis.

The test is capable of identifying methylation patterns in circulating tumour DNA in blood, which originate from both early-stage pancreatic adenocarcinomas and precancerous pancreatic lesions such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms.

See Also:

It will facilitate early detection and intervention for high-risk PDAC patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is undertaking the launch of a prospective study and clinical trial to assess and secure pre-market approval for PDACatch.

Singlera Genomics COO Qiang Liu said: “PDACatch is the first ever liquid biopsy tool to detect and monitor pancreatic adenocarcinoma. Early detection and monitoring of patients at high risk for pancreatic cancer will make a significant impact on these individuals’ quality of life.

“We look forward to working with the FDA as part of the Breakthrough programme to obtain continued guidance and prioritised reviews of our clinical trials and pre-market approval processes.”